Not an actual patient.

In clinical studies, many saw significant itch relief at 16 weeks, with some seeing results in 1 week. Many saw clear or almost clear skin at 16 and 52 weeks. Individual results may vary.

LEARN MORE

Full Prescribing Information

IMPORTANT SAFETY INFORMATION

INDICATION: NEMLUVIO^® (nemolizumab-ilto) is a prescription medicine used to treat adults with prurigo nodularis.

Contraindication: Known hypersensitivity to NEMLUVIO or any ingredients in NEMLUVIO.

Warnings/Precautions: Hypersensitivity reactions have been reported with NEMLUVIO use. You should not receive a live vaccine right before or during treatment with NEMLUVIO.

Adverse Events: Most common side effects of NEMLUVIO include: headache, skin rashes: atopic dermatitis (a type of eczema), eczema, and eczema nummular (scattered circular patches).

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/‌medwatch or call 1‑800‑FDA‑1088.

Please see full Prescribing Information including Patient Information.

©2026 Galderma Laboratories, L.P. All Rights Reserved.

NEMLUVIO is a registered trademark of Galderma.

US-NPN-2500005 01/26